CytoMed Long Term Debt To Capitalization from 2010 to 2025
| GDTC Stock | 2.61 0.05 1.88% |
Long Term Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter 0.0527 | Current Value 0.0501 | Quarterly Volatility 0.130032 |
Check CytoMed Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytoMed Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 66.2 K, Other Operating Expenses of 3.9 M or Research Development of 994 K, as well as many indicators such as Price To Sales Ratio of 317, Dividend Yield of 0.0 or PTB Ratio of 6.7. CytoMed financial statements analysis is a perfect complement when working with CytoMed Therapeutics Valuation or Volatility modules.
CytoMed | Long Term Debt To Capitalization |
Latest CytoMed Therapeutics' Long Term Debt To Capitalization Growth Pattern
Below is the plot of the Long Term Debt To Capitalization of CytoMed Therapeutics Limited over the last few years. It is CytoMed Therapeutics' Long Term Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytoMed Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt To Capitalization | 10 Years Trend |
|
Long Term Debt To Capitalization |
| Timeline |
CytoMed Long Term Debt To Capitalization Regression Statistics
| Arithmetic Mean | 0.24 | |
| Geometric Mean | 0.19 | |
| Coefficient Of Variation | 55.09 | |
| Mean Deviation | 0.08 | |
| Median | 0.25 | |
| Standard Deviation | 0.13 | |
| Sample Variance | 0.02 | |
| Range | 0.508 | |
| R-Value | (0.26) | |
| Mean Square Error | 0.02 | |
| R-Squared | 0.07 | |
| Significance | 0.33 | |
| Slope | (0.01) | |
| Total Sum of Squares | 0.25 |
CytoMed Long Term Debt To Capitalization History
About CytoMed Therapeutics Financial Statements
CytoMed Therapeutics stakeholders use historical fundamental indicators, such as CytoMed Therapeutics' Long Term Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although CytoMed Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in CytoMed Therapeutics' assets and liabilities are reflected in the revenues and expenses on CytoMed Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CytoMed Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Long Term Debt To Capitalization | 0.05 | 0.05 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of CytoMed Therapeutics Correlation against competitors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.